Stock Research for CGEN


Featured Broker: Ally Invest

Get the due diligence for another stock.


CGEN Stock Chart & Research Data

The CGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CGEN Due diligence Resources & Stock Charts

The CGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CGEN Detailed Price Forecast - CNN Money CNN View CGEN Detailed Summary - Google Finance
Yahoo View CGEN Detailed Summary - Yahoo! Finance Zacks View CGEN Stock Research & Analysis -

Stock Analysis

TradeIdeas View CGEN Trends & Analysis - Trade-Ideas Barrons View CGEN Major Holders - Barrons
NASDAQ View CGEN Call Transcripts - NASDAQ Seeking View CGEN Breaking News & Analysis - Seeking Alpha
Spotlight View CGEN Annual Report - OTC Report View CGEN OTC Short Report -
TradeKing View CGEN Fundamentals - TradeKing Charts View CGEN SEC Filings - Bar Chart
WSJ View Historical Prices for CGEN - The WSJ Morningstar View Performance/Total Return for CGEN - Morningstar
MarketWatch View the Analyst Estimates for CGEN - MarketWatch CNBC View the Earnings History for CGEN - CNBC
StockMarketWatch View the CGEN Earnings - StockMarketWatch MacroAxis View CGEN Buy or Sell Recommendations - MacroAxis
Bullish View the CGEN Bullish Patterns - American Bulls Short Pains View CGEN Short Pain Metrics -

Social Media Mentions

StockTwits View CGEN Stock Mentions - StockTwits PennyStocks View CGEN Stock Mentions - PennyStockTweets
Twitter View CGEN Stock Mentions - Twitter Invest Hub View CGEN Investment Forum News - Investor Hub
Yahoo View CGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View CGEN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CGEN - Insider Cow View Insider Transactions for CGEN - Insider Cow
CNBC View CGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CGEN - OTC Markets
Yahoo View Insider Transactions for CGEN - Yahoo! Finance NASDAQ View Institutional Holdings for CGEN - NASDAQ

Stock Charts

FinViz View CGEN Stock Insight & Charts - StockCharts View CGEN Investment Charts -
BarChart View CGEN Stock Overview & Charts - BarChart Trading View View CGEN User Generated Charts - Trading View

Latest Financial News for CGEN

Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial
Posted on Thursday September 20, 2018

HOLON, Israel, Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein, in patients with advanced solid tumors.  Under the terms of the collaboration and license agreement, Compugen is entitled to a milestone payment of $7.8 million at first patient dosing.

Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?
Posted on Friday September 14, 2018

Anyone researching Compugen Ltd (NASDAQ:CGEN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...

Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial
Posted on Friday September 07, 2018

HOLON, Israel, Sept. 7, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. PVRIG is a novel immune checkpoint identified by Compugen using its computational discovery capabilities. "Dosing the first patient with COM701, a first-in-class drug opportunity targeting a novel immune checkpoint we identified with our computational predictive platform, is a landmark event for us.

Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors
Posted on Wednesday September 05, 2018

HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of Oncology at Celgene Corporation, to its Board of Directors. "I am delighted to welcome Jean-Pierre to Compugen's Board," said Paul Sekhri, Chairman of the Board. "I am confident that his extensive experience in oncology drug development will prove invaluable to Compugen.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.